1. Home
  2. CBNK vs ASMB Comparison

CBNK vs ASMB Comparison

Compare CBNK & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBNK

Capital Bancorp Inc.

N/A

Current Price

$28.73

Market Cap

440.4M

Sector

Finance

ML Signal

N/A

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

N/A

Current Price

$29.14

Market Cap

440.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBNK
ASMB
Founded
1974
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
440.4M
440.0M
IPO Year
2018
2010

Fundamental Metrics

Financial Performance
Metric
CBNK
ASMB
Price
$28.73
$29.14
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$34.50
$43.40
AVG Volume (30 Days)
36.7K
93.3K
Earning Date
04-27-2026
01-01-0001
Dividend Yield
1.64%
N/A
EPS Growth
N/A
50.00
EPS
2.50
N/A
Revenue
N/A
N/A
Revenue This Year
$16.20
$33.33
Revenue Next Year
$8.52
N/A
P/E Ratio
$11.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.69
$7.76
52 Week High
$36.40
$39.71

Technical Indicators

Market Signals
Indicator
CBNK
ASMB
Relative Strength Index (RSI) 41.18 53.14
Support Level $27.43 $29.31
Resistance Level $29.83 $31.11
Average True Range (ATR) 1.14 1.79
MACD -0.22 0.14
Stochastic Oscillator 21.18 76.94

Price Performance

Historical Comparison
CBNK
ASMB

About CBNK Capital Bancorp Inc.

Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: